Renaissance Technologies LLC Sells 53,800 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Renaissance Technologies LLC decreased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 12.5% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 377,580 shares of the biopharmaceutical company's stock after selling 53,800 shares during the period. Renaissance Technologies LLC owned 0.30% of Halozyme Therapeutics worth $19,770,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Dimensional Fund Advisors LP boosted its position in Halozyme Therapeutics by 12.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,897,759 shares of the biopharmaceutical company's stock valued at $99,363,000 after acquiring an additional 209,530 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in shares of Halozyme Therapeutics by 4.9% during the second quarter. Envestnet Asset Management Inc. now owns 229,620 shares of the biopharmaceutical company's stock valued at $12,023,000 after purchasing an additional 10,651 shares in the last quarter. O Neil Global Advisors Inc. purchased a new stake in Halozyme Therapeutics in the second quarter worth $249,000. Federated Hermes Inc. raised its holdings in Halozyme Therapeutics by 37.8% in the second quarter. Federated Hermes Inc. now owns 696,131 shares of the biopharmaceutical company's stock worth $36,449,000 after purchasing an additional 191,030 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its position in Halozyme Therapeutics by 4.6% during the second quarter. DekaBank Deutsche Girozentrale now owns 57,453 shares of the biopharmaceutical company's stock valued at $2,963,000 after buying an additional 2,546 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Halozyme Therapeutics Stock Performance

HALO traded down $0.26 during trading on Friday, hitting $59.24. The company's stock had a trading volume of 2,685,512 shares, compared to its average volume of 1,264,345. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $65.53. The business's 50 day simple moving average is $58.40 and its 200-day simple moving average is $49.15. The company has a quick ratio of 6.21, a current ratio of 7.41 and a debt-to-equity ratio of 5.19. The firm has a market cap of $7.54 billion, a PE ratio of 24.48, a P/E/G ratio of 0.57 and a beta of 1.28.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last released its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.18. The company had revenue of $231.40 million for the quarter, compared to the consensus estimate of $204.94 million. Halozyme Therapeutics had a return on equity of 195.80% and a net margin of 38.62%. Halozyme Therapeutics's quarterly revenue was up 4.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.68 earnings per share. As a group, sell-side analysts predict that Halozyme Therapeutics, Inc. will post 3.7 EPS for the current fiscal year.

Analyst Ratings Changes

HALO has been the subject of several recent research reports. HC Wainwright reiterated a "buy" rating and set a $65.00 target price on shares of Halozyme Therapeutics in a report on Friday, September 13th. Wells Fargo & Company lifted their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an "overweight" rating in a report on Friday, June 7th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and increased their price target for the company from $52.00 to $57.00 in a report on Thursday. TD Cowen upped their price objective on Halozyme Therapeutics from $59.00 to $65.00 and gave the company a "buy" rating in a research report on Wednesday, August 7th. Finally, Morgan Stanley increased their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an "overweight" rating in a research note on Wednesday, August 7th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat, Halozyme Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $60.00.

Insider Buying and Selling

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $62.03, for a total transaction of $620,300.00. Following the transaction, the senior vice president now owns 173,756 shares of the company's stock, valued at $10,778,084.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, SVP Michael J. Labarre sold 10,000 shares of the business's stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $62.03, for a total value of $620,300.00. Following the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at $10,778,084.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Nicole Labrosse sold 5,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Monday, July 22nd. The shares were sold at an average price of $53.93, for a total value of $269,650.00. Following the sale, the chief financial officer now directly owns 15,480 shares in the company, valued at approximately $834,836.40. The disclosure for this sale can be found here. In the last ninety days, insiders sold 84,881 shares of company stock valued at $4,888,184. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.